Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- SCYX
- Price
- 0.99
- Stock movement up
- +0.12 (13.45%)
- Company name
- Scynexis Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 37.45M
- Ent value
- 49.23M
- Price/Sales
- 4.37
- Price/Book
- 0.64
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 3.48
- PEG
- -
- EPS growth
- -
- 1 year return
- -38.31%
- 3 year return
- -35.04%
- 5 year return
- -35.29%
- 10 year return
- -35.15%
Last updated: 2025-04-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
SCYX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 4.37 |
| Price to Book | 0.64 |
| EV to Sales | 5.75 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 37.94M |
| EPS (TTM) | -0.75 |
| FCF per share (TTM) | -0.45 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 8.57M |
| Gross profit (TTM) | -6.25M |
| Operating income (TTM) | -52.13M |
| Net income (TTM) | -36.44M |
| EPS (TTM) | -0.75 |
| EPS (1y forward) | 0.28 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -72.93% |
| Operating margin (TTM) | -608.57% |
| Profit margin (TTM) | -425.41% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 28.73M |
| Net receivables | 9.66M |
| Total current assets | 80.46M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 99.04M |
| Accounts payable | 4.96M |
| Short/Current long term debt | 15.90M |
| Total current liabilities | 25.72M |
| Total liabilities | 40.51M |
| Shareholder's equity | 58.53M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -21.84M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -21.84M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -62.26% |
| Return on Assets | -36.80% |
| Return on Invested Capital | -50.51% |
| Cash Return on Invested Capital | -30.27% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.90 |
| Daily high | 0.99 |
| Daily low | 0.90 |
| Daily Volume | 93K |
| All-time high | 145.00 |
| 1y analyst estimate | 6.67 |
| Beta | 1.50 |
| EPS (TTM) | -0.75 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 6 May 2025 |
Downside potential
Loading...
Downside potential data
| SCYX | S&P500 | |
| Current price drop from All-time high | -99.32% | -12.04% |
| Highest price drop | -99.45% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -83.07% | -11.07% |
| Avg time to new high | 249 days | 12 days |
| Max time to new high | 2571 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
37.45M
Marketcap category
Small-cap
Description
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Employees
29
Website
Investor relations
-
SEC filings
CEO
Marco Taglietti
Country
USA
City
Jersey City
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page